Rhabdomyosarcoma: An overview

Oncologist

Volumn 4, Issue 1, 1999, Pages 34-44

  Dagher, Ramzi ^a   Helman, Lee ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adjuvant chemotherapy; Radiation therapy; Rhabdomyosarcoma; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; TOPOTECAN; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; HUMAN; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHABDOMYOSARCOMA; TUMOR LOCALIZATION;

EID: 0033062014     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.4-1-34     Document Type: Review

References (80)

1. Young JL, Ries LG, Silverberg E et al. Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer 1986;58(suppl 2):598-602.
2. Kramer S, Meadows AT, Jarrett P et al. Incidence of childhood cancer: experience of a decade in a population-based registry. J Natl Cancer Inst 1983;70:49-55.
3. Wexler L, Helman L. Rhabdomyosarcoma and the undifferentiated sarcomas. In: Pizzo P, Poplack D, eds. Principles and Practice of Pediatric Oncology, 3rd Edition. Philadelphia: Lippincott-Raven, 1997:799-829.
4. Crist W, Gehan EA, Ragab AH et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610-630.
5. Wiener ES. Rhabdomyosarcoma. In: O'Neill JA, Rowe MI, Grosfeld JL et al., eds. Pediatric Surgery, 5th Edition. St Louis: Mosby, 1998:431-445.
6. Malkin D, Li FP, Strong LC et al. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-1238.
7. Diller L, Sexsmith E, Gottlieb A et al. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 1995;95:1606-1611.
8. Li M, Squire JA, Weksberg R. Molecular genetics of Beckwith-Wiedemann syndrome. Curr Opin Pediatr 1997;9:623-629.
9. Morison IM, Reeve AE. Insulin-like growth factor 2 and overgrowth: molecular biology and clinical implications. Mol Med Today 1998;4:110-115.
10. Turc-Carel C, Lizard-Nacol S, Justrabo E et al. Consistent chromosomal translocation in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet 1986;19:361-362.
11. Shapiro DN, Sublett JE, Li B et al. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res 1993;53:5108-5112.
12. Kelly KM, Womer RB, Sorensen PH et al. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J Clin Oncol 1997;15:1831-1836.
13. Scrable HJ, Witte DP, Lampkin BC et al. Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. Nature 1987;329:645-647.
14. Scrable H, Witte D, Shimada H et al. Molecular differential pathology of rhabdomyosarcoma. Genes Chromosomes Cancer 1989;1:23-35.
15. Zhan S, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 1994;94:445-448.
16. El Badry OM, Minniti C, Kohn EC et al. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1990;1:325-331.
17. Kalebic T, Tsokos M, Helman LJ. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res 1994;54:5531-5534.
18. Shapiro DN, Parham DM, Douglass EC et al. Relationship of tumor-cell ploidy to histologic subtype and treatment outcome in children and adolescents with unresectable rhabdomyosarcoma. J Clin Oncol 1991;9:159-166.
19. Pappo AS, Crist WM, Kuttesch J et al. Tumor-cell DNA content predicts outcome in children and adolescents with clinical group III embryonal rhabdomyosarcoma. The Intergroup Rhabdomyosarcoma Study Committee of the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol 1993;11:1901-1905.
20. Niggli FK, Powell JE, Parkes SE et al. DNA ploidy and proliferative activity (S-phase) in childhood soft-tissue sarcomas: their value as prognostic indicators. Br J Cancer 1994;69:1106-1110.
21. Pulciani S, Santos E, Lauver AV et al. Oncogenes in solid human tumours. Nature 1982;300:539-542.
22. Chardin P, Yeramian P, Madaule P et al. N-ras gene activation in the RD human rhabdomyosarcoma cell line. Int J Cancer 1985;35:647-652.
23. Ferracini R, Olivero M, Di Renzo MF et al. Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene 1996;12:1697-1705.
24. Newton WA, Gehan EA, Webber BL et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification - an Intergroup Rhabdomyosarcoma Study. Cancer 1995;76:1073-1085.
25. Maurer HM, Gehan EA, Beltangady M et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993;71:1904-1922.
26. Rodary C, Gehan EA, Flamant F et al. Prognostic factors in 951 nonmetastatic rhabdomyosarcoma in children: a report from the International Rhabdomyosarcoma Workshop. Med Pediatr Oncol 1991;19:89-95.
27. Tsokos M, Webber BL, Parham DM et al. Rhabdomyosarcoma. A new classification scheme related to prognosis. Arch Pathol Lab Med 1992;116:847-855.
28. Anderson JR, Link M, Qualman S et al. Improved outcome for patients with embryonal histology but not alveolar histology RMS: results from IRS-IV. Proc Am Soc Clin Oncol 1998;17:526a.
29. Parham DM, Webber B, Holt H et al. Immunohistochemical study of childhood rhabdomyosarcomas and related neoplasms. Results of an Intergroup Rhabdomyosarcoma Study project. Cancer 1991;67:3072-3080.
30. Dias P, Parham DM, Shapiro DN et al. Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma. Am J Pathol 1990;137:1283-1291.
31. Hosoi H, Sugimoto T, Hayashi Y et al. Differential expression of myogenic regulatory genes, MyoD1 and myogenin, in human rhabdomyosarcoma sublines. Int J Cancer 1992;50:977-983.
32. Tonin PN, Scrable H, Shimada H et al. Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development. Cancer Res 1991;51:5100-5106.
33. Mao L, Lee DJ, Tockman MS et al. Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci USA 1994;91:9871-9875.
34. Lawrence W, Hays DM, Moon TE et al. Lymphatic metastasis with childhood rhabdomyosarcoma. Cancer 1977;39:556-559.
35. Lawrence W, Hays DM, Heyn R et al. Lymphatic metastases with childhood rhabdomyosarcoma. A report from the Intergroup Rhabdomyosarcoma Study. Cancer 1987;60:910-915.
36. Wharam MD, Foulkes MA, Lawrence W et al. Soft tissue sarcoma of the head and neck in childhood: nonorbital and nonparameningeal sites. A report of the Intergroup Rhabdomyosarcoma Study (IRS)-I. Cancer 1984;53:1016-1019.
37. Wharam MD, Beltangady MS, Heyn RM et al. Pediatric orofacial and laryngopharyngeal rhabdomyosarcoma. An Intergroup Rhabdomyosarcoma Study report. Arch Otolaryngol Head Neck Surg 1987;113:1225-1227.
38. Raney RB, Gehan EA, Hays DM et al. Primary chemotherapy with or without radiation therapy and/or surgery for children with localized sarcoma of the bladder, prostate, vagina, uterus, and cervix. A comparison of the results in Intergroup Rhabdomyosarcoma Studies I and II. Cancer 1990;66:2072-2081.
39. Hays DM, Shimada H, Raney RB et al. Clinical staging and treatment results in rhabdomyosarcoma of the female genital tract among children and adolescents. Cancer 1988;61:1893-1903.
40. Mandell L, Ghavimi F, LaQuaglia M et al. Prognostic significance of regional lymph node involvement in childhood extremity rhabdomyosarcoma. Med Pediatr Oncol 1990;18:466-471.
41. Lawrence W, Hays DM, Heyn R et al. Surgical lessons from the Intergroup Rhabdomyosarcoma Study (IRS) pertaining to extremity tumors. World J Surg 1988;12:676-684.
42. Ortega JA, Wharam M, Gehan EA et al. Clinical features and results of therapy for children with paraspinal soft tissue sarcoma: a report of the Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1991;9:796-801.
43. Raney RB, Crist W, Hays D et al. Soft tissue sarcoma of the perineal region in childhood. A report from the Intergroup Rhabdomyosarcoma Studies I and II, 1972 through 1984. Cancer 1990;65:2787-2792.
44. Pollono DG, Tomarchio S, Berghoff R et al. Rhabdomyosarcoma of extrahepatic biliary tree: initial treatment with chemotherapy and conservative surgery. Med Pediatr Oncol 1998;30:290-293.
45. Gururangan S, O'Meara A, MacMahon C et al. Primary hepatic tumours in children: a 26-year review. J Surg Oncol 1992;50:30-36.
46. Celli P, Cervoni L, Maraglino C. Primary rhabdomyosarcoma of the brain: observations on a case with clinical and radiological evidence of cure. J Neurooncol 1998;36:259-267.
47. Attanasio A, Romitelli S, Mauriello A et al. Cardiac rhabdomyosarcoma: a clinicopathologic and electron microscopy study. G Ital Cardiol 1998;28:383-386.
48. Hays DM, Donaldson SS, Shimada H et al. Primary and metastatic rhabdomyosarcoma in the breast: neoplasms of adolescent females. A report from the Intergroup Rhabdomyosarcoma Study. Med Pediatr Oncol 1997;29:181-189.
49. Nielsen GP, Oliva E, Young RH et al. Primary ovarian rhabdomyosarcoma: a report of 13 cases. Int J Gynecol Pathol 1998;17:113-119.
50. Kedar A, Cantrel G, Rosen G. Rhabdomyosarcoma of the trachea. J Laryngol Otol 1988;102:735-736.
51. Koscielniak E, Rodary C, Flamant F et al. Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: a retrospective European multi-center analysis. Med Pediatr Oncol 1992;20:209-214.
52. Raney RB, Tefft M, Maurer HM et al. Disease patterns and survival rate in children with metastatic soft-tissue sarcoma. A report from the Intergroup Rhabdomyosarcoma Study (IRS)-I. Cancer 1988;62:1257-1266.
53. Kawasaki H, Takayama J, Nagasaki K et al. Hypercalcemia in children with rhabdomyosarcoma. J Pediatr Hematol Oncol 1998;20:327-329.
54. Ruymann FB, Thomas P. Disseminated intravascular coagulopathy, hypercalcemia, and hyperuricemia in rhabdomyosarcoma. In: Maurer HM, Ruymann FB, Pochedly C, eds. Rhabdomyosarcoma and Related Tumors in Children and Adolescents. Boca Raton: CRC Press, 1991:215.
55. Bahnson RR, Zaontz MR, Maizels M et al. Ultrasonography and diagnosis of pediatric genitourinary rhabdomyosarcoma. Urology 1989;33:64-68.
56. Kent DL, Haynor DR, Longstreth WT et al. The clinical efficacy of magnetic resonance imaging in neuroimaging. Ann Intern Med 1994;120:856-871.
57. Pappo AS, Shapiro DN, Crist WM. Rhabdomyosarcoma. Biology and treatment. Pediatr Clin North Am 1997;44:953-972.
58. Pedrick TJ, Donaldson SS, Cox RS. Rhabdomyosarcoma: the Stanford experience using a TNM staging system. J Clin Oncol 1986;4:370-378.
59. Lawrence W, Gehan EA, Hays DM et al. Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II). J Clin Oncol 1987;5:46-54.
60. Godzinski J, Flamant F, Rey A et al. Value of postchemotherapy bioptical verification of complete clinical remission in previously incompletely resected (Stage I and II pT3) malignant mesenchymal tumors in children: International Society of Pediatric Oncology 1984 Malignant Mesenchymal Tumors Study. Med Pediatr Oncol 1994;22:22-26.
61. Healey EA, Shamberger RC, Grier HE et al. A 10-year experience of pediatric brachytherapy. Int J Radiat Oncol Biol Phys 1995;32:451-455.
62. Gerbaulet AP, Esche BA, Haie CM et al. Conservative treatment for lower gynecological tract malignancies in children and adolescents: the Institut Gustave-Roussy experience. Int J Radiat Oncol Biol Phys 1989;17:655-658.
63. Ruymann F, Crist W, Wiener E et al. Comparison of two doublet chemotherapy regimens and conventional radiotherapy in metastatic rhabdomyosarcoma: improved overall survival using ifosfamide/etoposide compared to vincristine/melphalan in IRSG-IV. Proc Am Soc Clin Oncol 1997;16:521a.
64. IRSG. Actinomycin D and vincristine with or without radiation therapy, for newly diagnosed patients with low-risk rhabdomyosarcoma or undifferentiated sarcoma: an IRS-V protocol. Activation Date: Sept. 1, 1997.
65. Miser JS, Kinsella TJ, Triche TJ et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987;5:1191-1198.
66. IRSG. IRSV: A pilot study of vincristine (VCR), actinomycin-D (AMD), and escalating dose cydophosphamide (CTX) therapy for children with intermediate risk rhabdomyosarcoma and certain patients with metastatic rhabdomyosarcoma. Activation Date: October 1, 1996.
67. Frascella E, Pritchard-Jones K, Modak S et al. Response of previously untreated metastatic rhabdomyosarcoma to combination chemotherapy with carboplatin, epirubicin and vincristine. Eur J Cancer 1996;32A:821-825.
68. Pappo AS, Bowman LC, Furman WL et al. A phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma. J Pediatr Hematol Oncol 1997;19:438-442.
69. Vietti T, Crist W, Ruby B et al. Topotecan window in patients with rhabdomyosarcoma (RMS): an IRSG study. Proc Am Soc Clin Oncol 1997;16:510a.
70. IRSG. Topotecan and cyclophosphamide, followed by multimodal, multiagent therapy for children and adolescents with newly diagnosed stage IV/clinical group IV rhabdomyosarcoma, an IRS-V pilot study. Activation Date: April 25, 1996.
71. Horowitz ME, Kinsella TJ, Wexler LH et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 1993;11:1911-1918.
72. Koscielniak E, Klingebiel TH, Peters C et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 1997;19:227-231.
73. Raney B, Heyn R, Hays DM et al. Sequelae of treatment in 109 patients followed for 5 to 15 years after diagnosis of sarcoma of the bladder and prostate. A report from the Intergroup Rhabdomyosarcoma Study Committee. Cancer 1993;71:2387-2394.
74. Raney B, Ensign LG, Foreman J et al. Renal toxicity of ifosfamide in pilot regimens of the Intergroup Rhabdomyosarcoma Study for patients with gross residual tumor. Am J Pediatr Hematol Oncol 1994;16:286-295.
75. Lipshultz SE, Colan SD, Gelber RD et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808-815.
76. Ortega JA, Donaldson SS, Ivy SP et al. Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group, Children's Cancer Group, and the Pediatric Intergroup Statistical Center. Cancer 1997;79:2435-2439.
77. Heyn R, Haeberlen V, Newton WA et al. Second malignant neoplasms in children treated for rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee. J Clin Oncol 1993;11:262-270.
78. Kalebic T, Tsokos M, Helman LJ. Suppression of rhabdomyosarcoma growth by fumagillin analog TNP-470. Int J Cancer 1996;68:596-599.
79. Borgstrom P, Hillan KJ, Sriramarao P et al. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996;56:4032-4039.
80. Goletz TJ, Zhan S, Pendleton CD et al. Cytotoxic T cell responses against the EWS/FLI-1 Ewing's sarcoma fusion protein and the PAX3/FKHR alveolar rhabdomyosarcoma fusion protein. Proc Annu Meet Am Assoc Cancer Res 1996;37:A3243.